Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study

Inclusion Criteria: * 18-65 years old, no gender limit; * ECOG 0-2, estimated survival time ≥ 3 months; * Pathologically newly diagnosed with PTCL (except ALK+ anaplastic large cell lymphoma), with PR or CR after 6 cycles of induction chemotherapy; * Hb≥80g/L, ANC≥1.0×10\^9/L, PLT≥75×10\^9/L; TBIL≤1.5×ULN, ALT/AST≤2.0× ULN, Cr ≤1.5×ULN in the 14 days before enrollment * Have not received hematopoietic stem cell transplantation and other treatments within 4 weeks before enrollment; * The number of hematopoietic stem cells requires MNC ≥3×10\^8/kg and/or CD34 cells ≥2×10\^6/kg; * Informed consented Exclusion Criteria: * Accompanied by severe cardiac insufficiency, cardiac ejection fraction \<60%; or severe arrhythmia, intolerance of pretreatment; * Accompanied by severe pulmonary insufficiency (obstructive and or restrictive ventilatory disorders), intolerance of pretreatment; * Accompanied by severe liver function impairment, liver function indexes (ALT, TBIL) are more than 3 times higher than the upper limit of normal, intolerance of pretreatment; * Accompanied by severe renal insufficiency, the renal function index (Cr) is more than 2 times the upper limit of normal; or the 24-hour urine creatinine clearance rate Ccr is less than 50ml/min, intolerance of pretreatment; * Severe active infection before transplantation, intolerance of pretreatment; * Accompanied by brain dysfunction or severe mental illness, unable to understand or follow the research plan; * Pregnant or lactation； * Accompanied by other malignant tumors in need of treatment; * Patients who cannot guarantee the completion of the necessary treatment plan and follow-up observation.